Synthesis, physicochemical and preliminary pharmacological properties of N-[beta-hydroxy-gamma-(N-phenylpiperazinepropyl)]-2-pyrrolidinone.
The present paper reports on the synthesis and preliminary pharmacological properties of N-[beta-hydroxy-gamma-(N-phenylpiperazinepropyl)]-2- pyrrolidinone (MG-1). MG-1 was obtained by aminolysis of 1-(beta, gamma-epoxypropyl)-2-pyrrolidinone and N-phenylpiperazine. Its structure was established by elemental and spectral analyses (IR, UV, MS, 1H, 13C, 2D H-H and 2D C-H NMR). The antiarrhythmic activity of MG-1 was investigated on mice, rats and guinea pigs, using several models of arrhythmia. MG-1 attenuated or prevented the adrenaline- and barium chloride-induced arrhythmia. MG-1 demonstrated potent local anesthetic properties and depressed the depolarization phase of the action potential of cardiac cells. These results indicate that MG-1 possesses antiarrhythmic activity.
Malawska
B
B
Department of Pharmaceutical Chemistry, Medical Academy, Kraków, Poland.
Gorczyca
M
M
Filipek
B
B
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy; D004562:Electrocardiography / Q000187:drug effects; D005260:Female; D006168:Guinea Pigs; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D051379:Mice; D010210:Papillary Muscles / Q000187:drug effects* / Q000502:physiology; D010879:Piperazines / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D011760:Pyrrolidinones / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D013055:Spectrophotometry, Infrared; D013056:Spectrophotometry, Ultraviolet
D000889:Anti-Arrhythmia Agents; D010879:Piperazines; D011760:Pyrrolidinones; C081910:N-(beta-hydroxy-gamma-(N-phenylpiperazinepropyl))-2-pyrrolidinone